Cancer– tag –
-
Cancer Treatment Introductory–to–Basic Series – Part 8 (Final)
Life After Treatment and Survivorship: Shaping How You Live With and Beyond Cancer From Part 1 through Part 7 of this series, we have walked through the basics of cancer treatment: overall structure, differences in “curability” among Fro... -
Oncology Drug Approval News Flash：FDA approves durvalumab (Imfinzi) plus FLOT as perioperative therapy for resectable gastric and GEJ adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by sin... -
Cancer Treatment Introductory–to–Basic Series – Part 7
Standard Treatment, Clinical Trials, and Second Opinions: Making Informed Choices In earlier parts of this series, we looked at the overall framework of cancer treatment, differences in “curability” among cancer types, and how to th In e... -
Cancer Treatment Introductory–to–Basic Series – Part 5
Cancer-Specific “Curability”: Why Some Cancers Are Harder to Treat In the previous parts of this series, we looked at the overall framework of cancer treatment and introduced the main tools – surgery, drug therapy, radiotherapy, and part... -
Cancer Treatment Introductory–to–Basic Series – Part 6
Living with Recurrence and Metastasis: Cancer as a Long-Term Journey In Part 5, we explored why some cancers are considered “more curable” or “harder to cure,” focusing on the roles of stage, biology, and overall health. In Part 5, we ex... -
Oncology Drug Approval News Flash: FDA approves perioperative pembrolizumab plus enfortumab vedotin-ejfvfor cisplatin-ineligible muscle invasive bladder cancer (MIBC)
On November 21, 2025, the U.S. FDA approved pembrolizumab (Keytruda / Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant and adjuvant therapy for adults with muscle invasive bladder cancer (MIBC) who are e... -
Cancer Treatment Introductory–to–Basic Series – Part 4
Basics of Particle Therapy (Proton and Heavy-Ion): How It Differs from X-ray Radiotherapy In Part 3, we explored the basics of X-ray–based radiotherapy, including external beam radiation, brachytherapy, and high-precision techniques such... -
Oncology Drug Approval News Flash: FDA Grants Full Approval to Tarlatamab-dlle for ES-SCLC and Accelerated Approval to Sevabertinib for HER2-Mutated NSCLC
On November 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen) for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed after platinum... -
Oncology Drug Approval News Flash: FDA Approves Selumetinib (KOSELUGO) for Adults with Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, 2025, the U.S. Food and Drug Administration (FDA) approved selumetinib (KOSELUGO, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously appro... -
Oncology Drug Approval News Flash: FDA Approves Epcoritamab-bysp (Epkinly) with R² for Relapsed or Refractory Follicular Lymphoma
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly, Genmab / AbbVie) in combination with lenalidomide and rituximab (R²) for adults with relapsed or refractory follicular lymphoma (FL). T... -
Cancer Treatment: Introductory–to–Basic Series – Part 1
Understanding the Overall Picture of Cancer Treatment and Why Some Cancers Are “Easier” or “Harder” to Cure “Can cancer really be cured?” “If it comes back, does that mean it is over?” These are among the most common and most painful que... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 6 Final: BRD4 and CDK Crosstalk — The Future of Super-Enhancer Targeting)
From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. From Part 1 through Part 5, we explored CDK7/8/9/12/13/11 and their roles in transcriptional regulation. In this final installment, ... -
Oncology Drug Approval News Flash: FDA Approves Poherdy (pertuzumab-dpzb) as the First Interchangeable Biosimilar to Perjeta
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics) as the first interchangeable biosimilar to Perjeta (pertuzumab, Genentech). This marks a historic step in ex... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 5: CDK11 — Pause-Checkpoint and Emerging Therapeutic Potential)
In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. In Part 4, we examined CDK12/13 and their role in DNA repair and synthetic lethality. Here in Part 5, we focus on CDK11, a kinase that has recently gai... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 4: CDK12 & CDK13 — DNA Repair and Synthetic Lethality Strategies)
In Parts 1–3, we reviewed CDK7/8 and CDK9. In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of ge... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 3: CDK9 — The Bottleneck of Transcription Elongation and Clinical Development)
In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. In Parts 1 and 2, we introduced CDK7 and CDK8 in transcription initiation. Here in Part 3, we focus on CDK9, the central kinase controlling the transition from pa... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 2: CDK7 & CDK8 — Gatekeepers of Transcription Initiation and Emerging Therapeutics)
In Part 1, we reviewed the fundamentals of transcription and the CDK family. In Part 1, we reviewed the fundamentals of transcription and the CDK family. In this article, we focus on CDK7 and CDK8, two kinases that act at the transcripti... -
New Series｜Latest Therapeutic Trends — The Transcription Machinery as a Cancer Drug Target (Part 0: Introduction and Overview)
This series focuses on the transcriptional machinery as an emerging target for cancer therapy, highlighting CDK (Cyclin-Dependent Kinases) families involved in transcription and BRD4. This series focuses on the transcriptional machinery ... -
Oncology Drug Approval News Flash: FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma
On November 6, 2025, the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj, Janssen Biotech, Inc.) for the treatment of adults with high-risk smoldering multiple myeloma (SMM). This mark... -
Series: Decoding Cancer-Associated Cachexia — From Basics to Breakthroughs | Part 6 (Finale)
What’s Next — GDF15 Blockade and the Era of Precise Phenotypes Our finale focuses on near-future therapies and trial design. Our finale focuses on near-future therapies and trial design. Beyond “weight,” we target phenotype × mechanism a...
